178 related articles for article (PubMed ID: 33942339)
1. Reversible switching of primary cells between normal and malignant state by oncogenic virus KSHV and CRISPR/Cas9-mediated targeting of a major viral latent protein.
Ju E; Li T; Ramos da Silva S; Markazi A; Gao SJ
J Med Virol; 2021 Aug; 93(8):5065-5075. PubMed ID: 33942339
[TBL] [Abstract][Full Text] [Related]
2. Reduction of Kaposi's Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene.
Tso FY; West JT; Wood C
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651362
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Mediated Knockout and
BeltCappellino A; Majerciak V; Lobanov A; Lack J; Cam M; Zheng ZM
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413125
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus.
Liang Z; Qin Z; Riker AI; Xi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):1400-1405. PubMed ID: 33092788
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Kaposi's sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells.
Haddad CO; Kalt I; Shovman Y; Xia L; Schlesinger Y; Sarid R; Parnas O
Virol J; 2021 Mar; 18(1):56. PubMed ID: 33731154
[TBL] [Abstract][Full Text] [Related]
7. Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin.
Lu J; Jha HC; Verma SC; Sun Z; Banerjee S; Dzeng R; Robertson ES
J Virol; 2014 Apr; 88(8):4204-17. PubMed ID: 24478433
[TBL] [Abstract][Full Text] [Related]
8. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 Screening of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Cells Identifies XPO1 as a Vulnerable Target of Cancer Cells.
Gruffaz M; Yuan H; Meng W; Liu H; Bae S; Kim JS; Lu C; Huang Y; Gao SJ
mBio; 2019 May; 10(3):. PubMed ID: 31088931
[TBL] [Abstract][Full Text] [Related]
10. Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication.
Garrigues HJ; Howard K; Barcy S; Ikoma M; Moses AV; Deutsch GH; Wu D; Ueda K; Rose TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978712
[TBL] [Abstract][Full Text] [Related]
11. A CRISPR-Cas9 screen identifies mitochondrial translation as an essential process in latent KSHV infection of human endothelial cells.
Holmes DL; Vogt DT; Lagunoff M
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28384-28392. PubMed ID: 33122441
[TBL] [Abstract][Full Text] [Related]
12. Bub1 in Complex with LANA Recruits PCNA To Regulate Kaposi's Sarcoma-Associated Herpesvirus Latent Replication and DNA Translesion Synthesis.
Sun Z; Jha HC; Robertson ES
J Virol; 2015 Oct; 89(20):10206-18. PubMed ID: 26223641
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus.
Bigi R; Landis JT; An H; Caro-Vegas C; Raab-Traub N; Dittmer DP
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):E11379-E11387. PubMed ID: 30429324
[TBL] [Abstract][Full Text] [Related]
14. Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus.
Qin Z; Dai L; Slomiany MG; Toole BP; Parsons C
Cancer Res; 2010 May; 70(10):3884-9. PubMed ID: 20406987
[TBL] [Abstract][Full Text] [Related]
15. Nuclear Localization and Cleavage of STAT6 Is Induced by Kaposi's Sarcoma-Associated Herpesvirus for Viral Latency.
Wang C; Zhu C; Wei F; Gao S; Zhang L; Li Y; Feng Y; Tong Y; Xu J; Wang B; Yuan Z; Robertson ES; Cai Q
PLoS Pathog; 2017 Jan; 13(1):e1006124. PubMed ID: 28099521
[TBL] [Abstract][Full Text] [Related]
16. Kaposi's Sarcoma-Associated Herpesvirus LANA-Adjacent Regions with Distinct Functions in Episome Segregation or Maintenance.
Juillard F; De León Vázquez E; Tan M; Li S; Kaye KM
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626680
[TBL] [Abstract][Full Text] [Related]
17. Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice.
Jeong JH; Hines-Boykin R; Ash JD; Dittmer DP
J Virol; 2002 Nov; 76(21):11024-32. PubMed ID: 12368345
[TBL] [Abstract][Full Text] [Related]
18. KSHV Genome Replication and Maintenance in Latency.
Ueda K
Adv Exp Med Biol; 2018; 1045():299-320. PubMed ID: 29896673
[TBL] [Abstract][Full Text] [Related]
19. The Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Inhibits Expression of SUMO/Sentrin-Specific Peptidase 6 To Facilitate Establishment of Latency.
Lin X; Sun R; Zhang F; Gao Y; Bin L; Lan K
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615201
[TBL] [Abstract][Full Text] [Related]
20. Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A.
Kim KY; Huerta SB; Izumiya C; Wang DH; Martinez A; Shevchenko B; Kung HJ; Campbell M; Izumiya Y
J Virol; 2013 Jun; 87(12):6782-93. PubMed ID: 23576503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
